Your browser doesn't support javascript.
loading
Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
Lentz, S R; Misgav, M; Ozelo, M; Salek, S Z; Veljkovic, D; Recht, M; Cerqueira, M; Tiede, A; Brand, B; Mancuso, M E; Seremetis, S; Lindblom, A; Martinowitz, U.
Affiliation
  • Lentz SR; Department of Internal Medicine, The University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA. steven-lentz@uiowa.edu
Haemophilia ; 19(5): 691-7, 2013 Sep.
Article in En | MEDLINE | ID: mdl-23647704
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Factor VIII / Hemophilia A Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Aged / Child / Humans / Male / Middle aged Language: En Journal: Haemophilia Journal subject: HEMATOLOGIA Year: 2013 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Factor VIII / Hemophilia A Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Aged / Child / Humans / Male / Middle aged Language: En Journal: Haemophilia Journal subject: HEMATOLOGIA Year: 2013 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido